{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:31:37Z","timestamp":1783780297658,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A primary pulmonary invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive adenocarcinoma of the lung. The prognosis of advanced IMA depending on chemotherapy regimen has not been fully investigated. Here, we compared the clinical outcomes of patients with advanced IMA treated with different palliative chemotherapies that included novel therapeutics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This single-center retrospective study included a total of 79 patients diagnosed with IMA and treated with palliative chemotherapy. The primary outcome was the comparison of overall survival according to palliative chemotherapy type. Risk factors associated with death were evaluated as a secondary outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study cohort of 79 patients comprised 27 progressive or recurrent cases and 52 initial metastatic patients. Thirteen patients (16.5%) received targeted therapy and 18 cases (22.8%) received immunotherapy. When we compared the survival outcomes of the different treatment regimens, patients with IMA treated by immunotherapy (undefined vs. non-immunotherapy 17.0\u2009months, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) had better overall survival rates. However, there was no difference in the prognosis between the cases treated with a targeted therapy (35.6 vs. non-targeted therapy 17.0\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.211). None of the conventional regimens produced a better outcome. By multivariable analysis, immunotherapy (HR 0.28; 95% CI 0.11\u20130.74; <jats:italic>P<\/jats:italic>\u2009=\u20090.008) was found to be an independent prognostic factor for death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study suggests that immunotherapy for patients with advanced IMA may provide favorable outcomes than other chemotherapy options.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08472-6","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:02:37Z","timestamp":1624698157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung"],"prefix":"10.1186","volume":"21","author":[{"given":"Yoon Jung","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-gon","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinkyo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonjun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-0259","authenticated-orcid":false,"given":"Jae Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"issue":"2","key":"8472_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","volume":"6","author":"WD Travis","year":"2011","unstructured":"Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer\/american thoracic society\/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244\u201385. https:\/\/doi.org\/10.1097\/JTO.0b013e318206a221.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"8472_CR2","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","volume":"10","author":"A Marx","year":"2015","unstructured":"Marx A, Chan JK, Coindre JM, et al. The 2015 World Health Organization classification of tumors of the thymus: continuity and changes. J Thorac Oncol. 2015;10(10):1383\u201395. https:\/\/doi.org\/10.1097\/JTO.0000000000000654.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"8472_CR3","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00432-016-2201-9","volume":"142","author":"J Luo","year":"2016","unstructured":"Luo J, Wang R, Han B, Zhang J, Zhao H, Fang W, et al. Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma. J Cancer Res Clin Oncol. 2016;142(8):1837\u201345. https:\/\/doi.org\/10.1007\/s00432-016-2201-9.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7689","key":"8472_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354. https:\/\/doi.org\/10.1038\/nature25183.","journal-title":"Nature"},{"issue":"8","key":"8472_CR5","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1097\/JTO.0000000000000579","volume":"10","author":"HS Shim","year":"2015","unstructured":"Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Hoang Ho Q, et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J Thorac Oncol. 2015;10(8):1156\u201362. https:\/\/doi.org\/10.1097\/JTO.0000000000000579.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"8472_CR6","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/j.humpath.2013.05.026","volume":"44","author":"H Ichinokawa","year":"2013","unstructured":"Ichinokawa H, Ishii G, Nagai K, Kawase A, Yoshida J, Nishimura M, et al. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. Hum Pathol. 2013;44(12):2636\u201342. https:\/\/doi.org\/10.1016\/j.humpath.2013.05.026.","journal-title":"Hum Pathol"},{"key":"8472_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.lungcan.2016.11.004","volume":"102","author":"YJ Cha","year":"2016","unstructured":"Cha YJ, Kim HR, Lee HJ, Cho BC, Shim HS. Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. Lung Cancer. 2016;102:82\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2016.11.004.","journal-title":"Lung Cancer"},{"key":"8472_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.humpath.2017.08.002","volume":"71","author":"JM Boland","year":"2018","unstructured":"Boland JM, Maleszewski JJ, Wampfler JA, Voss JS, Kipp BR, Yang P, et al. Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous\/nonmucinous adenocarcinoma-a clinicopathological and molecular genetic study with survival analysis. Hum Pathol. 2018;71:8\u201319. https:\/\/doi.org\/10.1016\/j.humpath.2017.08.002.","journal-title":"Hum Pathol"},{"issue":"5","key":"8472_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/ajcp\/aqx170","volume":"149","author":"G Lin","year":"2018","unstructured":"Lin G, Li H, Kuang J, Tang K, Guo Y, Han A, et al. Acinar-predominant pattern correlates with poorer prognosis in invasive mucinous adenocarcinoma of the lung. Am J Clin Pathol. 2018;149(5):373\u20138. https:\/\/doi.org\/10.1093\/ajcp\/aqx170.","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"8472_CR10","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.jtho.2016.03.011","volume":"11","author":"HY Lee","year":"2016","unstructured":"Lee HY, Cha MJ, Lee KS, Lee HY, Kwon OJ, Choi JY, et al. Prognosis in resected invasive mucinous adenocarcinomas of the lung: related factors and comparison with resected nonmucinous adenocarcinomas. J Thorac Oncol. 2016;11(7):1064\u201373. https:\/\/doi.org\/10.1016\/j.jtho.2016.03.011.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"8472_CR11","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.21037\/jtd.2018.06.09","volume":"10","author":"SW Moon","year":"2018","unstructured":"Moon SW, Choi SY, Moon MH. Effect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study. J Thorac Dis. 2018;10(6):3595\u2013608. https:\/\/doi.org\/10.21037\/jtd.2018.06.09.","journal-title":"J Thorac Dis"},{"issue":"10066","key":"8472_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299\u2013311. https:\/\/doi.org\/10.1016\/S0140-6736(16)30958-8.","journal-title":"Lancet"},{"issue":"22","key":"8472_CR13","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1801005.","journal-title":"N Engl J Med"},{"issue":"21","key":"8472_CR14","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1810865.","journal-title":"N Engl J Med"},{"issue":"21","key":"8472_CR15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1910231.","journal-title":"N Engl J Med"},{"issue":"7","key":"8472_CR16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","volume":"30","author":"AT Shaw","year":"2019","unstructured":"Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdz131.","journal-title":"Ann Oncol"},{"issue":"9","key":"8472_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1704795.","journal-title":"N Engl J Med"},{"key":"8472_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ctrv.2018.04.006","volume":"66","author":"A Leonetti","year":"2018","unstructured":"Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, et al. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev. 2018;66:82\u201394. https:\/\/doi.org\/10.1016\/j.ctrv.2018.04.006.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"8472_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243\u201360. https:\/\/doi.org\/10.1097\/JTO.0000000000000630.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"8472_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2015.09.009.","journal-title":"J Thorac Oncol"},{"issue":"8","key":"8472_CR21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","volume":"30","author":"K Bergethon","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863\u201370. https:\/\/doi.org\/10.1200\/JCO.2011.35.6345.","journal-title":"J Clin Oncol"},{"issue":"25","key":"8472_CR22","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138. https:\/\/doi.org\/10.1056\/NEJMoa0909530.","journal-title":"N Engl J Med"},{"issue":"5","key":"8472_CR23","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/03007995.2018.1547273","volume":"35","author":"KB Winfree","year":"2019","unstructured":"Winfree KB, Torres AZ, Zhu YE, Muehlenbein C, Aggarwal H, Woods S, et al. Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting. Curr Med Res Opin. 2019;35(5):817\u201327. https:\/\/doi.org\/10.1080\/03007995.2018.1547273.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"8472_CR24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537\u201346. https:\/\/doi.org\/10.1200\/JCO.18.00149.","journal-title":"J Clin Oncol"},{"issue":"6","key":"8472_CR25","doi-asserted-by":"publisher","first-page":"e0178420","DOI":"10.1371\/journal.pone.0178420","volume":"12","author":"AP Abernethy","year":"2017","unstructured":"Abernethy AP, Arunachalam A, Burke T, McKay C, Cao X, Sorg R, et al. Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. PLoS One. 2017;12(6):e0178420. https:\/\/doi.org\/10.1371\/journal.pone.0178420.","journal-title":"PLoS One"},{"issue":"2","key":"8472_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.tranon.2019.12.004","volume":"13","author":"L Lei","year":"2020","unstructured":"Lei L, Wang WX, Yu ZY, Liang XB, Pan WW, Chen HF, et al. A real-world study in advanced non-small cell lung cancer with KRAS mutations. Transl Oncol. 2020;13(2):329\u201335. https:\/\/doi.org\/10.1016\/j.tranon.2019.12.004.","journal-title":"Transl Oncol"},{"issue":"12","key":"8472_CR27","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-14-0107","volume":"20","author":"T Nakaoku","year":"2014","unstructured":"Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res. 2014;20(12):3087\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0107.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"8472_CR28","doi-asserted-by":"publisher","first-page":"462","DOI":"10.15252\/emmm.201606711","volume":"9","author":"M Guo","year":"2017","unstructured":"Guo M, Tomoshige K, Meister M, Muley T, Fukazawa T, Tsuchiya T, et al. Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Mol Med. 2017;9(4):462\u201381. https:\/\/doi.org\/10.15252\/emmm.201606711.","journal-title":"EMBO Mol Med"},{"issue":"5","key":"8472_CR29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.21037\/tlcr.2017.06.10","volume":"6","author":"YJ Cha","year":"2017","unstructured":"Cha YJ, Shim HS. Biology of invasive mucinous adenocarcinoma of the lung. Transl Lung Cancer Res. 2017;6(5):508\u201312. https:\/\/doi.org\/10.21037\/tlcr.2017.06.10.","journal-title":"Transl Lung Cancer Res"},{"key":"8472_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ebiom.2019.02.049","volume":"41","author":"H Adderley","year":"2019","unstructured":"Adderley H, Blackhall FH, Lindsay CR. KRAS-mutant non-small cell lung cancer: converging small molecules and immune checkpoint inhibition. EBioMedicine. 2019;41:711\u20136. https:\/\/doi.org\/10.1016\/j.ebiom.2019.02.049.","journal-title":"EBioMedicine"},{"issue":"2","key":"8472_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.molcel.2013.02.018","volume":"50","author":"EL Snyder","year":"2013","unstructured":"Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, et al. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell. 2013;50(2):185\u201399. https:\/\/doi.org\/10.1016\/j.molcel.2013.02.018.","journal-title":"Mol Cell"},{"issue":"4","key":"8472_CR32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1165\/rcmb.2009-0018OC","volume":"42","author":"R Kettle","year":"2010","unstructured":"Kettle R, Simmons J, Schindler F, Jones P, Dicker T, Dubois G, et al. Regulation of neuregulin 1\u03b21-induced MUC5AC and MUC5B expression in human airway epithelium. Am J Respir Cell Mol Biol. 2010;42(4):472\u201381. https:\/\/doi.org\/10.1165\/rcmb.2009-0018OC.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"8472_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1158\/2159-8290.CD-13-0633","volume":"4","author":"L Fernandez-Cuesta","year":"2014","unstructured":"Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014;4(4):415\u201322. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0633.","journal-title":"Cancer Discov"},{"issue":"13","key":"8472_CR34","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1917239.","journal-title":"N Engl J Med"},{"issue":"10","key":"8472_CR35","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1007\/s12325-019-01057-7","volume":"36","author":"L Incorvaia","year":"2019","unstructured":"Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, et al. Programmed death ligand 1 (PD-L1) as a predictive biomarker for pembrolizumab therapy in patients with advanced non-small-cell lung cancer (NSCLC). Adv Ther. 2019;36(10):2600\u201317. https:\/\/doi.org\/10.1007\/s12325-019-01057-7.","journal-title":"Adv Ther"},{"issue":"143","key":"8472_CR36","first-page":"155","volume":"26","author":"R Chen","year":"2018","unstructured":"Chen R, Tao Y, Xu X, Shan L, Jiang H, Yin Q, et al. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. Discov Med. 2018;26(143):155\u201366.","journal-title":"Discov Med"},{"issue":"22","key":"8472_CR37","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1801946.","journal-title":"N Engl J Med"},{"issue":"1","key":"8472_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5761\/atcs.oa.18-00163","volume":"25","author":"T Miyazawa","year":"2019","unstructured":"Miyazawa T, Marushima H, Saji H, Kojima K, Hoshikawa M, Takagi M, et al. PD-L1 expression in non-small-cell lung cancer including various adenocarcinoma subtypes. Ann Thorac Cardiovasc Surg. 2019;25(1):1\u20139. https:\/\/doi.org\/10.5761\/atcs.oa.18-00163.","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"2","key":"8472_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","volume":"4","author":"CK Lee","year":"2018","unstructured":"Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):210\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4427.","journal-title":"JAMA Oncol"},{"issue":"1","key":"8472_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41416-018-0234-3","volume":"120","author":"F Passiglia","year":"2019","unstructured":"Passiglia F, Cappuzzo F, Alabiso O, Bettini AC, Bidoli P, Chiari R, et al. Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. Br J Cancer. 2019;120(1):57\u201362. https:\/\/doi.org\/10.1038\/s41416-018-0234-3.","journal-title":"Br J Cancer"},{"key":"8472_CR41","doi-asserted-by":"publisher","first-page":"CD010383","DOI":"10.1002\/14651858.CD010383.pub2","volume":"5","author":"J Greenhalgh","year":"2016","unstructured":"Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016;5:CD010383. https:\/\/doi.org\/10.1002\/14651858.CD010383.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"8472_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/pin.12879","volume":"70","author":"R Wakejima","year":"2020","unstructured":"Wakejima R, Inamura K, Ninomiya H, Nagano H, Mun M, Okumura S, et al. Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma. Pathol Int. 2020;70(2):72\u201383. https:\/\/doi.org\/10.1111\/pin.12879.","journal-title":"Pathol Int"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08472-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08472-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08472-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:03:55Z","timestamp":1624698235000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08472-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8472"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08472-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"13 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Asan Medical Center Institutional Review Board, Seoul, Korea (IRB No.2020\u20130645). The same ethics committee (the Asan Medical Center Institutional Review Board, Seoul, Korea) confirmed the requirement for the patients\u2019 informed consent was waived because of the retrospective nature and minimal risk to the subjects. Administrative permission to access the clinical data used in this study has been granted by the Asan Medical Center Institutional Review Board, Seoul, Korea. It was conducted in full accordance with the Guidelines for Good Clinical Practice and the 1964 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"731"}}